Kim HN, Newcomb CW, Carbonari DM, et al. - In a multi‐cohort study of HIV/hepatitis B (HBV)‐coinfected individuals, the predictors of hepatocellular carcinoma (HCC) were analyzed. Researchers enrolled HIV/HBV‐coinfected persons within 22 cohorts of the North American AIDS Cohort Collaboration on Research and Design (1995‐2016). Cox regression was applied to ascertain adjusted hazard of factors assessed at cohort entry (age, gender, race, body mass index), ever during observation (heavy alcohol use, hepatitis C), or time‐updated (HIV RNA, CD4+ percentage, diabetes mellitus, HBV DNA). In this analysis, 115 HCC cases were diagnosed over 65,392 person‐years (incidence rate, 1.8 [95% CI, 1.5‐2.1] events/1,000 person‐years) among 8,354 HIV/HBV‐coinfected individuals (median age, 43 years; 93% male; 52.4% non‐white). The results exhibited that HIV/HBV‐coinfected individuals on antiretroviral therapy (ART) with detectable HBV viremia are still at risk for HCC. Sustained HBV suppression is necessary to gain maximal benefit from ART for HCC prevention.